FDA gives tentative approval to Dr. Reddy's generic of HIV prevention shot lenacapavir

The FDA tentatively approved Dr. Reddy's generic lenacapavir, a $40-a-year HIV prevention shot for 120 poorer countries.

Objective Facts

The U.S. Food and Drug Administration granted tentative approval on November 2, 2026, to Dr. Reddy's Laboratories for a generic, long-acting injectable version of lenacapavir for HIV prevention, Unitaid said in a statement from Geneva. Becker's Hospital Review, citing a Clinton Health Access Initiative release, reported it is the first generic HIV prevention injection to reach this stage, roughly 16 months after Gilead's Yeztugo was approved in June 2025. Tentative approval is the FDA's standard status for generics while the brand drug is still under patent: it allows U.S. government procurement but no U.S. commercial sales. Dr. Reddy's has agreed to sell the twice-yearly shot for $40 per person per year in the 120 low- and middle-income countries covered by the voluntary license Gilead granted it in October 2024, with initial supplies expected before the end of 2026. Indian coverage, led by Business Standard, focused on the achievement for an Indian manufacturer and the remaining steps, including WHO prequalification and country-by-country approvals.

Deep Dive

Gilead signed royalty-free voluntary licenses with six generic manufacturers, including Dr. Reddy's, in late 2024 to supply lenacapavir to 120 mostly low- and middle-income countries, Unitaid said. In September 2025, Dr. Reddy's signed a deal with Unitaid, the Wits Reproductive Health and HIV Institute and the Clinton Health Access Initiative (CHAI) that set the $40 annual price and funded development work. Becker's Hospital Review reported that Dr. Reddy's sped up its timeline by bundling the prevention and treatment uses into one 505(b)(2) application and requesting priority review, which targets a decision within six months. Unitaid executive director Philippe Duneton told Business Standard that generic copies usually trail the original by about a decade and that this one took just over a year. The partner statements put the most weight on price and speed. Unitaid noted that $40 a year puts the shot in line with daily oral PrEP, which it called a key condition for uptake. ThePrint, by contrast, reported the originator price at about $28,000 a year. Several sources flagged limits on what the approval does. Pharmacally wrote that it does not authorize U.S. sales or approve the drug in any individual country, and it said the clinical results from Gilead's PURPOSE 1 and PURPOSE 2 trials should not be read as new efficacy data for the generic. Saiqa Mullick of Wits RHI said in the Unitaid release that "an affordable drug alone is not enough," pointing to provider training and community outreach. The next steps are WHO prequalification and national registrations in the licensed countries, which Business Standard listed as conditions for wider access. Unitaid said more than 125,000 people in 10 African early-adopter countries have already started Gilead's branded shot, so the first generic shipments promised for late 2026 will show whether supply can scale. Readers should also watch whether the other five licensees, among them Emcure and Hetero, follow with their own FDA filings.

Regional Perspective

Business Standard reported the tentative approval on the evening of November 2, India time, and led with Deepak Sapra, Dr. Reddy's chief executive for API and services, who said, "This is a moment of immense pride for all of us at Dr Reddy's." The paper said the approval came under the PEPFAR program, set out the $40 annual price agreed with Unitaid, Wits RHI and CHAI, and listed WHO prequalification and national approvals as the steps still ahead. Our searches turned up Indian wire and trade coverage as well, but Deccan Herald's report could not be opened, so it is not cited here. Indian coverage put more weight on the manufacturer than U.S. trade outlets did. Becker's Hospital Review focused on FDA procedure and the 505(b)(2) pathway, while Business Standard framed the decision around Indian scientific and manufacturing capacity. Indian outlets also linked the news to the drug's prospects at home. ThePrint reported on August 25 that a CDSCO expert committee recommended waiving local Phase III and bioequivalence trials for Dr. Reddy's and Emcure versions of the prevention shot, though not for Emcure's treatment application. For India, the stakes run in two directions: export income from supplying 120 countries and possible access for Indian patients. ThePrint said the eventual Indian price remains unclear. Chetali Rao of Third World Network told ThePrint that without the trial waiver, local studies could have taken "one-and-a-half, two years."

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisPolicy GuideAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

FDA gives tentative approval to Dr. Reddy's generic of HIV prevention shot lenacapavir

The FDA tentatively approved Dr. Reddy's generic lenacapavir, a $40-a-year HIV prevention shot for 120 poorer countries.

Nov 3, 2026· Updated Nov 4, 2026
What's Going On
  • On November 2, 2026, the FDA granted tentative approval to Dr. Reddy's Laboratories for a generic version of lenacapavir, the twice-yearly HIV prevention injection Gilead sells as Yeztugo, according to Unitaid and Business Standard.
  • Becker's Hospital Review reported that tentative approval lets the U.S. government buy the drug but bars sales in the U.S. market while Gilead's patents remain in force.
  • Dr. Reddy's will charge $40 per person per year in the 120 low- and middle-income countries covered by Gilead's 2024 voluntary license, with first supplies expected before the end of 2026 and wider availability in 2027.
  • The decision came about 16 months after Gilead's own product won FDA approval in June 2025; Unitaid and Becker's credited a combined 505(b)(2) filing that qualified for priority review.
  • Indian outlets Business Standard and ThePrint framed the approval as a win for Indian drugmakers and tied it to a separate push to bring generic lenacapavir to Indian patients.
Region says: Indian coverage treated the FDA decision as a milestone for an Indian drugmaker, with Business Standard focusing on company pride and the remaining regulatory steps abroad.
Objective Deep Dive

Gilead signed royalty-free voluntary licenses with six generic manufacturers, including Dr. Reddy's, in late 2024 to supply lenacapavir to 120 mostly low- and middle-income countries, Unitaid said. In September 2025, Dr. Reddy's signed a deal with Unitaid, the Wits Reproductive Health and HIV Institute and the Clinton Health Access Initiative (CHAI) that set the $40 annual price and funded development work. Becker's Hospital Review reported that Dr. Reddy's sped up its timeline by bundling the prevention and treatment uses into one 505(b)(2) application and requesting priority review, which targets a decision within six months. Unitaid executive director Philippe Duneton told Business Standard that generic copies usually trail the original by about a decade and that this one took just over a year.

The partner statements put the most weight on price and speed. Unitaid noted that $40 a year puts the shot in line with daily oral PrEP, which it called a key condition for uptake. ThePrint, by contrast, reported the originator price at about $28,000 a year. Several sources flagged limits on what the approval does. Pharmacally wrote that it does not authorize U.S. sales or approve the drug in any individual country, and it said the clinical results from Gilead's PURPOSE 1 and PURPOSE 2 trials should not be read as new efficacy data for the generic. Saiqa Mullick of Wits RHI said in the Unitaid release that "an affordable drug alone is not enough," pointing to provider training and community outreach.

The next steps are WHO prequalification and national registrations in the licensed countries, which Business Standard listed as conditions for wider access. Unitaid said more than 125,000 people in 10 African early-adopter countries have already started Gilead's branded shot, so the first generic shipments promised for late 2026 will show whether supply can scale. Readers should also watch whether the other five licensees, among them Emcure and Hetero, follow with their own FDA filings.

◈ Tone Comparison

Coverage was largely celebratory and close to the partner press releases. Business Standard led with company pride, while Pharmacally took a more cautious line, calling the decision a regulatory milestone rather than completed deployment in countries.